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Economics valuing the market at $400 billion 
in 2018.[1] This covers a wide variety of 
IMDs from orthopedic to cardiovascular 
implants, such as stents. Stents are nor-
mally tubular, with a circular cross sec-
tion, implantable vascular scaffold devices 
that retain their shape when deployed in 
a vessel. Stents have varied deployment 
locations from within the biliary duct to 
coronary artery; all use the stent to reopen 
blocked vessels. As such the stent market 
is worth $7.98 billion with 67.3% of this 
from coronary stents alone.[2] This market 
is driven by the global epidemic of cardio-
vascular disease (CVD).[3] Cardiovascular 
disease is in fact an umbrella term for a 
variety of diseases that range from myo-
cardial infarctions to strokes to chronic 
kidney disease. In 2016 coronary artery 
disease (CAD), the formation of athero-
sclerotic plaques in coronary arteries, 
accounted for ≈9.43 million deaths world-
wide making it the largest killer in the 
world.[3] The American Heart Association 
predicts the direct and indirect costs, loss of work hours, of 
CVD to reach $1.1 trillion in 2035.[1] As such the use of IMDs, 
specifically stents, to overcome CVD is urgent and a rapidly 
developing field.
The coronary blood supply consists of a left and right-
sided system that supplies blood to the muscle of the heart. 
This consists of three main coronary arteries; (1) left anterior 
descending artery and (2) circumflex artery, and the (3) right 
coronary artery, which have smaller side arteries that form 
side branches. Like the main vessels these side branches have 
a reduced diameter, the further they are from their origin at 
the aorta until they transition into the micro vasculature. A 
highly established and effective tool for treating CAD is percu-
taneous coronary intervention (PCI). This technique involves 
inserting a series of catheters and guiding wires through the 
patients skin into their artery, either radially from the wrist’s 
brachial artery or less commonly now the leg’s femoral artery. 
During the procedure, the catheter is thread up through the 
arterial vasculature to the point of occlusive disease within the 
coronary blood supply of the heart. Then, a stent mounted on a 
thin balloon is inflated and deployed by being passed through 
the catheters. The balloon initially pushes back the plaque 
material; a product of decades long accumulated fat deposits 
and cellular components including smooth muscle cells, and 
inflammatory cells inside the vessel wall, freeing the lumen of 
obstruction.[4] Then the metal stent on the balloon expands in 
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1. Introduction
Today, the implantable medical devices (IMDs) and technology 
market have expanded rapidly with the United States Office of 
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turn with the balloon but on deflation of the balloon the stent 
remains in an expanded form in the vessel to stop the plaque 
recoiling and re-encroaching of the plaque back into the lumen 
that can cause postoperative ischemic events (Figure 1). The 
number of PCIs performed in the United Kingdom (UK) 
in 2015 reached 97 376 and with an ageing population the 
number of cases is only set to continue rising over the coming 
years.[5] Due to its success, a greater number of people are sur-
viving CAD and many of these patients live with a stent for the 
remainder of their lives.
PCI is highly beneficial with patients treated having 
improved symptoms, it has increased comfort due to the proce-
dure being vastly less invasive than coronary artery heart bypass 
graft surgery, and it has significantly reduced costs and led 
to faster in-hospital recovery.[6] However, the procedure has a 
nemesis known as in-stent restenosis (ISR), which is when cell 
overgrowth termed restenosis occurs close to or in the stents 
themselves. In the first generation of bare metal stents (BMS) 
17%–41% of implants developed ISR.[7] The second generation 
of stents had drugs coated on the stent to inhibit restenosis. 
These drug eluting stents (DES) are coated with antiprolifera-
tives, a drug coating that inhibits cell growth, such as Paclitaxel 
or Sirolimus, or similar derivatives. Paclitaxel is a cytoskeletal 
drug that is an anti-tubulin that stops microtubules formation 
and thus limits neointima growth.[8] While Sirolimus is an 
mTOR inhibitor and thus reduces vascular smooth muscle cell 
proliferation.[9] Secondary benefits of these coatings decrease 
ISR via the prevention of platelet aggregation, fibrin deposition, 
and clot formation, thus increased risk of stent thrombosis. 
Indeed patients are left on antiplatelet medication to prevent 
blood clot formation for many months after PCI.
Previous research has reported mortality from stent 
thrombosis occluding the vessel to be between 11% and 42% 
causing a type of heart attack termed ST elevation myocardial 
infarctions (STEMIs),[10] whereby the ST segment of a patient’s 
electrocardiogram is elevated due to the underpinning heart dis-
ease.[11] However, this was reported to be reduced to 2% mortality 
due to STEMIs from stent thrombosis but STEMIs induced by 
stent thrombosis were still reported at 11%.[12] As such the risks 
imposed by ISR can be deadly. Several trials have been under-
taken to compare the efficacy of DES over BMS, as the review 
will highlight. With DES ISR was reduced to <10%.[7] However, 
the odds ratio (OR) of ISR in multivessel disease increases signif-
icantly even with DES deployment in two-vessel disease, where 
two out of the three coronary arteries are affected (OR: 2.922; 
95% confidence interval (CI): 1.266–6.745; p = 0.012), or three-
vessel disease (OR: 2.574; 95% CI: 1.128–5.872; p = 0.025).[13] 
With risks still prevalent after DES, alternate stenting devices is a 
field of high innovation and significant research interest.[4]
This review highlights developments in coronary artery stents 
by evaluating the previous bare metal stents and drug eluting 
stents technologies. We then assess bioresorbable stents (BRS) 
that are currently available, but with their own limitations. Within 
this, a brief overview of emerging bioresorbable stents is com-
pared. Current research for stents and related vascular technolo-
gies is then discussed. Within this several microelectromechanical 
systems (MEMS) are reviewed with a vascular focus. An overview 
of some of the current challenges that limit these devices from 
being human ready vascular IMDs is finally discussed.
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2. Established Stenting Technology
The UK National Institute for Health and Care Excellence 
(NICE) has suggested the use of DES for diseased coronary 
vessels with a diameter of <3.0 mm or with atheroscle-
rotic lesions >15 mm in length. Posthumous analysis in the 
BASKET-PROVE trial highlighted that ISR for BMS versus 
DES was 5.4% versus 0.76%, respectively; p < 0.001, with 
improvements at lengths and vessels outside of these.[14] 
Kereiakes in a propensity matched analysis for dual antiplatelet 
therapy (DAPT) improvements at 12 months compared to 33 
months reported major adverse cardiac and cerebrovascular 
events (MACCEs) and total death to be reduced in the DES 
at 33 months than the BMSs group (respectively, 11.4% vs 
13.2%; p = 0.053 and 4.2% vs 5.1%; p = 0.16).[15] Although not 
statistically significant, the total stent thrombosis was signifi-
cantly reduced in DESs compared to BMS, respectively, 1.7% 
versus 2.6%; p = 0.01, with MACCE showing a noninferiority, 
p = < 0.001. Marco Valgimiglis group assessed whether poten-
tial DES recipients who were receiving similar DAPT longevi-
ties would benefit additionally from a DES over a BMS. Again, 
all course mortality showed no significant difference between 
DES and BMS, respectively, 11.1% versus 11.4%; p = 0.83.[16] 
However, definite or probable stent thrombosis between the 
groups was significantly decreased, DES 2.0% versus BMS 
4.1%; p = 0.019. This showed that an appropriate length of 
DAPT with DES would decrease stent thrombosis potentially 
improving long-term outcomes. Sabaté in the EXAMINA-
TION trial at 1 year showed improvements in DES over BMS 
for stent thrombosis and target vessel revascularization (TVR), 
respectively, 0.9% versus 2.5%; p = 0.019 and 3.7% versus 
6.8%; p = 0.0077.[17] However at 5 year analysis of stent throm-
bosis had no significant difference between DES and BMS, 
respectively, 2% versus 2%; p = 0·25; however, TVR was lower 
in DES compared to BMS, respectively, 7% versus 10%; p = 
0.009.[18] Although the stent thrombosis was similar in both 
stent groups, the reduction in retreating the culprit vessel 
notes potentially cost saving and improved patient quality 
of life (QOL) by reducing the costs of intervention. How-
ever, Feinberg in a Cochrane database meta-analysis reported 
that DES did not significantly decrease the risks of absolute 
death or major adverse cardiac events (MACE) (BMS vs DES, 
respectively, absolute death 7.74% vs 6.97%; MACE 6.63% vs 
6.36%).[19] Feinberg also stated that the studies reviewed did 
not assess patient QOL and as such DES may not improve 
QOL long term in patients.[19]
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Figure 1. Schematic of atherosclerosis plaque formation over time and stenting devices within a coronary artery. Created with BioRender.com.
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3. Evaluation of Current Bioresorbable Stenting 
Solutions
3.1. Benefits and Limitations of Bioresorbable Stents
The latest advance in stenting technologies is the development of 
BRS that overcome many of the limitations of metal stents. 
BRS can be made of natural substances such as cornstarch 
and will naturally degrade overtime during the healing process 
post-PCI. These stents have been introduced to overcome the 
challenges that a nondegradable BMS and DES face. These 
challenges include first that BMS and DES are permanent 
additions to the vessels that can never be removed, and they 
can also permanently disrupt the fine endothelial layer of the 
artery, disrupting the normal physiological conditions of the 
artery that leads to endothelial dysfunction.[20] Second, the flow 
of blood through a stented artery is different to that of a non-
diseased patent artery and this change in flow condition can 
also affect the endothelium function.[20] Third, as these stents 
are permanent implants systemic antiplatelet therapy is needed 
for a lengthy period after implantation to prevent blood clots. 
A reduced conformity to the vessel in complex individuals can 
also lead to side branch blocking in these patients.[21] While the 
long-term polymer exposure may be related to chronic inflam-
mation and hypersensitivity.[22]
In contrast BRS have the unique ability to overcome many 
of these issues. After implantation they are eventually broken 
down and dissolve into the blood. This characteristic overcomes 
the need for long-term antiplatelet therapy, removing the risk 
of local hypersensitivity and chronic inflammation.[21] Once 
dissolved BRS aim to leave a normal patent vessel with unin-
terrupted blood flow. The removal of the stent also has the 
potential to reinstate the vasoconstrictive properties of the 
vessel to sustain natural blood flow.
3.2. Effects of Construction Materials on Bioresorbable Stents
The magic of BRS degradation and its duration is dependent on 
the construction material used within the stent. The constructs 
can be of a polymer base or a corrosive metal that naturally 
degrades overtime. Polymers commonly from the monomer 
poly-L-lactide (PLLA) with derivatives of poly-D,L-lactide (PDLLA) 
or ultrahigh-molecular-weight PLLA are not uncommon.[23] 
Polymer-based stents with the additive of polylactic acid cross 
linked within them have increased longevity of stent degrada-
tion. PLLA in comparison the PDLA-based stent can only with-
stand degradation longer than by up ≈20 months.[24] However, 
metallic stents have an increased tensile modulus allowing for 
less deformity and risk of recoil with a thinner stent strut. To 
overcome this a polymer-based stent needs a thicker stent strut 
that can therefore impede the flow of blood through the artery 
and instigate ISR.[24] Polymer-based stents also have the draw-
back of being radiopaque, which makes imaging of the device 
difficult even with markers placed on the device.[25]
Metallic constructs for BRS undergo a corrosive process in 
order to remove the stent from the artery. These metallic-based 
stents are visible under imaging and have performed simi-
larly to metal stents due to their similar content. However, the 
corrosive effect can lead to rapid degradation of the stent and 
as restenosis can occur up to 18 months after deployment this 
may be suboptimal. Magnesium succumbs to this rapid degra-
dation while having a tensile strength that allows for minimal 
recoil.[26] To increase the longevity of a magnesium-based stent 
the incorporation of nicotinamide adenine dinucleotide can 
add protective layers to the stent.[27] Magnesium stents offer 
a high tensile strength but were subject to cracking during 
deployment due to a low elastic strength.[28] Manganese and 
tin were added to create a magnesium alloy that had decreased 
the rate of stent degradation while improving the mechanical 
properties for the stent.[29] Manganese is of particular interest 
due to the inflammatory system interactions that are associated 
with CVD. Iron BRS were shown to have greater conformity 
to the vessel due to a higher elasticity modulus with no ISR 
noted at <18 months.[30] In addition to this iron constructed 
stents have an increased longevity compared to a magnesium 
stent while also having greater strength allowing for slimmer 
stent struts.[31–33] The addition of manganese to iron stents cre-
ates an anti-ferromagnetic alloy, thus potentially allowing for 
magnetic resonance imaging compatibility.[34] Zinc alone is not 
mechanically suitable for stents due to poor tensile strength 
and being a relatively soft metal. Alloys of zinc can utilize the 
malleability of the metal to produce a conforming device that 
in vivo studies have shown to have intermediate resistance to 
the corrosive process. The alloys of zinc include magnesium 
and manganese that have previously shown biocompatibility 
and efficacy for magnesium as a stent.[25] Interestingly a zinc 
calcium alloy has also been investigated for future use; how-
ever, the effects of calcium release in an already diseased vessel 
are as yet unclear.[35]
3.3. Comparison of Clinical Outcomes with Bioresorbable Stents
Clinicians have welcomed the use of BRS to reduce ISR. How-
ever, the initial Abbot Absorb stent had a troubled beginning 
with late intrasegmental failure and recoil resulting in a pause 
in sales, although recent articles are showing acceptable and 
noninferior results .[20,36,37] Several companies have entered 
the market with different designs and construction materials. 
One of the major findings from the failures with BRS, but also 
established stents, was that the stent strut size was too large 
and induced turbulent flow, which resulted in the activation 
of platelets causing coagulation (Figure 2). As such, ultrathin 
stent, ≈100 µm, struts have been explored for all stents but also 
for helping improve BRS.
Results from BRS clinical trials have not had the initial sig-
nificant impact that clinicians hoped BRS would bring. The 
BIOFLOW V trial compared drug elution polymers and stent 
strut thickness. They compared market leading stents such as 
the Orsiro BRS by Biotronik to the Xience durable polymer (DP) 
everolimus-eluting stent (EES) by Abbott Vascular. Subgroup 
analysis found that patients who presented with acute coronary 
syndromes, an umbrella term for MIs and unstable angina,[11] 
showed that BRS with ultrathin struts were non-inferior to the 
standard DP-EES.[38] Target lesion failure (TLF), defined as the 
composite of cardiovascular death, target vessel related MI, or 
ischemia-driven target lesion revascularization (TLR), in the 
BRS was significantly improved over the DP-EES, respectively, 
5.6% versus 11.0%; p = 0.023. However, TLR and total stent 
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thrombosis showed no significant improvement in incidences, 
respectively, 3.5% versus 3.9%; p = 0.823 and 0.5% versus 1.0%; 
p = 0.601. Similarly, Byrne in the BRS Absorb stent,[39] Abbott 
Vascular, when implanted for patients suffering an MI no sig-
nificant reductions in future MI or TLR were noted when com-
pared to the Xience, respectively, 1.8% versus 3.4%; p = 0.51 
and 4.8% versus 5.7%; p = 0.84. Pilgrim at 5 year follow-up of 
Orsiro BRS versus Xience DP-EES showed no significant dif-
ference in TLF,[40] TLR, or stent thrombosis; however, all cause 
mortality was increased in the Orsiro, respectively 14·1% 
versus 10·3%; p = 0·017. de Winter investigating in the DES-
SOLVE III trial of a Sirolimus-eluting BRS,[41] MiStent by 
Stentys, versus Xience again showed TLR, definite stent throm-
bosis and MACE to all have no significant improvements 
over the DP-EES. Quantification of neointimal hyperplasia 
by optical coherence tomography optical coherence tomo-
graphy (OCT) showed area, volume, and obstruction of neoin-
timal hyperplasia to be reduced in the BRS over the DES, area 
0·98 versus 1·31 mm2; p = 0·0022, volume 19·6 versus 32·6 mm3; 
p = 0·0150 and obstruction 15·0% versus 18·9%; p = 0·0081.[26] 
In a first-in-human head-to-head comparison of two different 
BRS Tenekecioglu compared the novel spiral design Mirage,[42] 
Manli Cardiology, against the Absorb by OCT. This showed 
that at 12 months the Mirage stent had a stenosis obstruction 
of 28.6% while the Absorb was 18.2%, p = 0.046, although the 
spiral design did not outperform the traditional design, refine-
ment of the design may lead to future success. Gasior evalu-
ating the ALEX,[43] Balton, Sirimlous-eluting BRS compared to 
the Xience DP-EES reported similar results again in TVR and 
all stent thrombosis to previous studies after 1 year follow-up, 
5.88% versus 4.61%; p = 0.10 and 1.46% versus 1.21%; p = 0.54. 
Wlodarczak in an initial report of the Magmaris,[44] Biotronik, 
BRS reports in hospital TLR in 1 out of the 50 patient cohort, 
however at 6 months no subsequent TLR or stent thrombosis. 
Picard produced a meta-analysis on the most recent randomized 
control trails of BRS with the conclusion that BRS to be nonin-
ferior to second-generation DES,[45] with the major end points 
all being nonsignificant, TLR 1.8% versus 1.8%; p = 0.93, stent 
thrombosis 0.4% versus 0.5%; p = 0.85 and MACE 7.0% versus 
6.2%; p = 0.43.
Several iterations of BRS are being researched and trailed with 
many concluding noninferiority to current DES. With no defini-
tive results consistently being produced to date this new solution 
to atherosclerosis and ISR will continue to be developed. As such 
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Figure 2. a) Schematic of a stent strut causing disruption of the laminar blood flow resulting in platelet aggregation and reduction in vasomotive 
signaling molecules. b) A histological cross section of a stent strut surrounded by atherosclerotic platelet legion; the blood flow here was left to right. 
c) Schematic of an ultrathin stent strut promoting laminar flow keeping an intact endothelial barrier and allowing vasodilation promoters to act. d) A 
histological cross section of an ultrathin stent strut with minimal platelet aggregation surrounding the strut. NO, nitric oxide; PGI2, prostacyclin; TF, 
tissue factor; TFPI, tissue factor pathway inhibitor; TM, thrombomodulin; tPA, tissue plasminogen activator; vWF, von Willebrand factor; X, coagulation 
factor X; and Xa, activated coagulation factor X. Reproduced with permission.[20] Copyright 2018, Springer Nature GmbH.
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stent technology is set to continue to explore and expand the 
types of materials for construction, design of the stent, but also 
how the stent can be utilized to provide the best quality of care.
4. Toward an Integrated Self-Reporting  
Stent Sensor
After a stent is deployed a silent wound response termed unde-
tected ISR post PCI can have fatal consequences. It is a blockage 
or narrowing of the vessel at the site the stent was deployed 
at. It can manifest with the same deadly consequences as that 
of the original CAD. Early diagnosis of ISR is currently almost 
impossible to detect and it relies on the patient having signifi-
cant chest pain or worse a second cardiac event. Those patients 
fortunate to have their ISR detected still rely on lifelong medi-
cation that may require subsequent PCI with additional DES 
deployment or drug eluting balloons. These are major under-
takings on often already unwell patients and can lead to other 
major and costly surgical interventions such as coronary artery 
bypass grafting.[46]
Being able to remotely detect when stents are beginning 
to occlude would have a major impact on patient welfare, 
hospital inpatient costs, and decreasing the risk of major 
adverse events occurring unexpectedly outside the hospital 
environment. A solution are stents with integrated sensors 
that can detect growth of cells, the different cell types, and 
those can measure changes in flow and pressure across the 
lesion site. A way of achieving this within a limited space is 
through on stent MEMS technology. These devices will rely 
on Poiseuille and Bernoulli’s equations for detecting differ-
ences of pressure and flow at two given points across the 
stent (Figure 3a).[47] As such stents integrated with sensors 
and using of such devices will offer an advanced solution to 
ISR detection and potentially wirelessly reporting changes 
before clinical symptoms manifest.
4.1. Capacitance Resonator Sensors in Stents
Another method of measuring vessel pressure wirelessly 
within harsh conditions was first shown by Fonseca for the 
use in aero plane engines operating at 0–7 bar of pressure.[48] 
These sensors utilized a passive inductance and capacitance 
resonator. This consists of a cavity with electrodes either end 
that are connected to each other and acts as a variable capac-
itor. Please see Figure 3b for a cross sectional diagram and 
a constructed sensor diagram. Furthering work on passive 
inductance and capacitance resonator sensor Luo created a 
biodegradable version of the sensor,[49] aiming for biomedical 
applications, with use in saline and air an operating range 
of 0–20 kPa was successfully measured with a sensitivity of 
39 kHz kPa−1. The sensor was successfully stable in transmit-
ting data for up to 86 h after immersion in saline; however, 
this was not submersed for the full 86 h. Chen created a thin 
and flexible version of the sensor and tested it in vivo using 
mice.[50] This biocompatibility resulted in Park integrating the 
inductance sensor into a stent that was subsequently tested 
within a pressurized chamber to assess the sensor.[51] An 
operating range of 0–230 mmHg was established with a sensi-
tivity of 43 kHz mmHg−1. Furthering this work Park decreased 
the size of the sensor and integrated the sensor inside of the 
stent instead of previously outside the stent.[52] Operating at 
148 MHz with a sensing range of 0–220 mmHg when within 
an artificial artery, however without fluid, a linear relation 
of 60 kHz mmHg−1 was noted. Oliveira using an inductive 
pressure sensor upon an aortic aneurysm graft did produce 
fluidic-based pressure measurements.[53] This was performed 
Adv. Sci. 2019, 1900856
Figure 3. Different sensor designs. a) Schematic of stent and pressure sensors in a vessel with in-stent restenosis. b) Cross sectional schematic and 
visualization of a biodegradable capacitance and resonator sensor. Adapted with permission.[49] Copyright 2014, IEEE. c) Diaphragmatic pressure 
sensor with deflection of a silicon membrane when pressure is applied. Adapted under the terms of the Attribution 4.0 International (CC BY 4.0) 
license.[66] Copyright 2018, The Authors, Published by Wiley-VCH. d) Magnetoelastic resonance sensor incorporated within a stent scaffold. Adapted 
under the terms of the Attribution 3.0 International (CC BY 3.0) license.[56] Copyright 2017, The Authors, Published by IOP Publishing.
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through tubing with the stent graft over an artificial aneurysm 
section and a commercial pressure sensor placed before the 
graft to assess the pressure. The water flow was controlled by 
a tap that was opened and closed to mimic pulsatile flow with 
in the aorta. The sensor changed frequency in correspondence 
to the change in pressure and post analysis was able to identify 
frequency response for the respective pressures. Park in 
another study tested the sensor and antenna in vivo within a rat 
with successful measurement of the intravascular blood pres-
sure; however,[54] this was not integrated into the stent.
4.2. Magnoelastic Resonant Sensors in Stents
An alternate approach to detecting the change in flow was 
devised by Green and Gianchandani based around the reso-
nance of magnoelastic materials,[55] those whose magnetic sus-
ceptibility changes upon the application of mechanical stress 
such as Metglas and Elgiloy. The first two generations showed 
a proof of concept that biliary sludge could be detected as 
well as differentiate between healthy and nonhealthy sludge. 
Viswanath explored stenosis build up in peripheral artery 
disease using these sensors within a stent (Figure 3d).[56] The 
stent and sensor were tested under flow using a peristaltic 
pump and successfully differentiated between diastolic and 
systolic pulses due to pressure changes translating into reso-
nant difference created during systole. Following this in situ 
and in vivo testing was performed, which showed device inter-
rogation at 7.5 cm was successful in transmitting data outside 
of the porcine mode.[57] Further, in vivo testing of the sensor 
was unsuccessful due to damage of the resonators used in 
the sensor. The device however was biocompatible but did 
not show any signs of sludge formation after 1 month of 
implantation.[57] The packaging of the stent was redesigned 
to account for the damage sustained during implantation, 
mainly caused due to mechanical bending during the implant 
of the device. The two redesigns, one stiffer and one less stiff, 
were both tested under stress on the bench and in situ with 
the most flexible reporting in situ successfully; however, no in 
vivo work was produced at this iteration.[58] The in vivo work 
that has been performed with this sensor type has been made 
possible by identifying the use of peripheral stenting devices 
and utilizing the larger scale of these stents to allow attach-
ment of sensors with greater ease.
4.3. Silicon Diaphragm Pressure Sensors in Stents
Due to the common metallic nature of stents the idea of incor-
porating an antenna into the stent scaffold was proposed by 
Takahata.[59] The stent antenna, termed “stentenna,” used micro 
machined foil, which was attached to a silicon diaphragm pres-
sure sensor. This inductive coupled stentenna successfully 
assessed pressure under flow in a mock artery. Mohammadi 
built upon this work coating the stents in copper and gold in 
order to improve the inductance of the antenna.[60] On coating 
the helical stentenna and applying a frequency of 150 MHz the 
quality factor, a measure of resonator characteristics, increased 
to 35 for copper and to 31 for gold from a starting point of 5. 
The stainless steel stent peaked at 5 when a 150 MHz resonant 
frequency was applied. Thin film diaphragmatic transducers 
(Figure 3c) were investigated for increased pressure sensi-
tivity. These sensors had a linear relation between capacitance 
increase and pressure increase while having a response time 
of 0.43 ms under dynamic flow.[61] Thus, suitability for sensing 
beat to beat pressure would be possible at high human heart 
rates. Chen coated the gold stentenna with parylene C to insu-
late the electronics of the stent and prevent their degradation;[62] 
parylene was chosen due to its biocompatibility.[63] In vitro flow 
modeling of the parylene C coated stent showed a frequency 
response from 0 to 78 mmHg over an increasing flow rate of 
0–900 mL min−1. With intracoronary flow in severe coronary 
artery stenosis measured at a mean of 2.54 ± 0.55 mL s−1 and 
stenosed vessels at a mean of 4.81 ± 1.95 mL s−1, this varying 
flow rate represents a working physiological range.[64] Although 
the sensor was only half as sensitive during the flow experi-
ments compared to stationary experiments, this did identify 
that the sensor was sensitive to flow rates, an important moni-
toring option. The stent was successfully integrated into a com-
mercial graft and deployed in swine and confirmed through 
angiography. After initial pressure recordings the stent stopped 
transmitting which they speculated to be caused by an electrical 
fault due to mechanical bending during the procedure or graft 
clotting. To improve the robustness of the sensor under the 
crimping of the stent to the balloon and mechanical bending 
encountered under insertion Chen introduced laser microw-
elding of a redesigned sensor to the stentenna.[65] This ongoing 
research has cumulated with the recent publication of Chen 
where a stent was crimped to a balloon at >100 Newton’s and 
was inflated within a graft.[66] Successful wireless interrogation 
through the graft allowed for data transfer until graft occlusion 
due to thrombosis caused by repeated compression and relaxa-
tion of the graft in order to vary pressure. The diaphragmatic 
sensor showed sensitivity within the required limits of the 
systemic and coronary circulation systems. The stentenna 
design reduces the electrical componentry through the novel 
integration to the stent scaffold and as such has the potential to 
decrease the electronic footprint a telemetric stent would have 
within a vessel.
4.4. Biosensors for Neurological Stents
Although this review focuses on CAD atherosclerosis stents 
are also clinically used for diseases found in other vessels and 
are treated in a similar methodology. These stents too can 
develop ISR. The use of stents with sensors within carotid 
arteries and cerebrovasculature of the brain therefore rep-
resents a deployment area opportunity and has also been 
pursued. Brox using the stentenna investigated the depths of 
transmission in which the signal could be detected.[67] When 
immersed in saline the stent was not detected at a distance 
12.5 mm from the receiver, thus not suitable for deployment 
within the chest cavity. More suitable areas of deployment 
were identified in superficial areas like the carotid artery. 
Chen produced a highly flexible mesh, stretching increase 
of >500% in the radial axis,[68] thus being robust enough 
for applications in a flow diverter stent for the treatment of 
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cerebral aneurysms. This mesh was then integrated with 
nanofabricated capacitance flow sensors.[69] Flow was detected 
for a maximum of 10 min due to the electrodes dissolution, 
gold fabricated electrodes outperformed the longevity of 
Nitinol and magnesium constructed electrodes. Work within 
the endovascular of the cerebral cortex has produced a deploy-
able electrode array across the motor cortex of ewes within a 
Nitinol-based stent.[70] Previous investigations of these sen-
sors within this design noted that the wireless telemetry was 
ultimately the limiting factor for device progression.[71,72] 
Importantly, assessment of electrode integration into the stent 
design did not limit flow or induce malignancies.[71,72]
4.5. Complementary Metal–Oxide–Semiconductors  
within Stents
DeHennis and Wise showed that flow and pressure were feasible 
detections for an implantable,[73] wireless and battery-free 
device. A description between the degree of occlusion to the 
changes in flow and pressure was also presented in their paper 
(Figure 4). This was achieved through a BiCMOS, the combi-
nation of bipolar (Bi) junction transistors and complementary 
metal–oxide–semiconductor (CMOS) transistors. A CMOS 
allows for high density transistors and low power consumption, 
thus a power but efficient sensor. However, CMOS transistors 
are susceptible to noise more so than BiCMOSs. A BiCMOS 
integrate the low operational voltage of bipolar junctional tran-
sistors and their low input and output impedance with the logic 
benefits of a CMOS. Although this increased the cost of a device 
and the complexity of the device is increased, the result is a 
highly sensitive, robust, and efficient device is produced. This 
resulted in the detection of a reduction in flow of 13%, which is 
the equivalence of a 3 mmHg pressure drop. Furthering work 
on CMOS embedded stents Chow produced a high sensitivity 
sensor,[74] 0.5 mmHg with an average error of 1.268 mmHg, 
and tested it in vitro over a range of pressure 0–50 mmHg. The 
stent itself was used as the antenna for the device and resulted 
in a transmission capability of 10 cm to 1 m when implanted 
in vivo at 3.5 cm in swine. These results within stents show the 
high performance[75,76] and accuracy that CMOS-based MEMS 
are recognized. Further investigations into CMOS-based stent 
sensors are likely due to their low production costs and pro-
bable further size reductions.
4.6. Sensors with Stenting Applications
The reviewed MEMS have been integrated into stenting devices 
for use in varied sites from the biliary duct to cerebral veins. 
Novel and emerging sensors are yet to be integrated into stents 
but potential integration would be highly beneficial. Pulse wave 
velocity (PWV) is the measurement of how the blood pressure 
pulse travels through the blood vessels to assess the elasticity 
of the vessel. This measure could therefore be used to detect 
stiffening, an important determinant of hypertension.[77] A 
novel biodegradable sensor based on poly(glycerol sebacate) was 
used to measure pulse wave velocity in vitro. The multielectrode 
array had high sensitivity with capacitive changes unique when 
a bee (22.5 mg) and a grain of rice (21.8 mg) were measured.[78] 
The authors propose a cardiac patch with the sensor built into 
it; however, another use due to the high sensitivity and flexibility 
may be within a coronary stent for pressure measurements.
Attaching sensors to the outside of a graft was shown by 
Milner using a pressure sensor and aortic aneurysm graft.[79] 
As such many of the sensors discussed have also used and 
been in used in grafts. A novel approach potentially for graft 
occlusion detection is through Doppler ultrasonography.[80] A 
wireless Doppler probe within a cuff is attached to the artery 
and the velocity of blood can be detected, which in turn allows 
for pressure and also the detection of occlusion.[81,82] Multiple 
sensors outside of a graft could allow for a Doppler image of 
the whole grafted vessel that is consistent with the Doppler 
flow images vascular sonographers are familiar with. Another 
alternate measurement system though hydrostatic pressure 
measurements made possible by a microbubble-based MEMS 
showed that impedance changes correlated to pressure.
Alternatively, molecular markers of ISR could be detected 
at a cellular level using protein molecular sensors. Several 
biosensors that investigate the proliferation the of cells and 
also the biochemical changes that this causes are in develop-
ment.[83] Electrical impedance spectroscopy has the potential 
to accommodate the detection of cellular proliferation with 
endothelial cells successfully detected.[84,85] These sensors 
offer the ability to characterize cells and clots with current 
uses in catheters and a stent seeking clinical approval.[86–88] 
Alternatively, endothelial dysfunction and vascular remod-
eling biochemical markers associated with ISR are another 
possible avenue. This can include inflammatory markers 
such as TNF or other markers like fibrin and nitric oxide.[88] 
Investigations into sensors for the detection of these markers 
through impedance spectroscopy are promising, especially 
with oncology, however are not yet stent based.[89] The use of 
impedance-based sensors due to their miniaturization capa-
bilities, accuracy, and multiple detection capabilities could be 
a powerful tool for future vascular applications.
Adv. Sci. 2019, 1900856
Figure 4. Graphical representation of flow rate and pressure changes 
caused by varying degrees of occlusion. Theoretical curve with a compar-
ison to a measured curve by a BiCMOS. Reproduced with permission.[73] 
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5. Future Considerations
One of the key enabling technologies for IMDs is the Internet 
of Things (IoT), specifically the medical IoT. In a Forbes article 
the global value of the medical IoT alone was estimated to be 
on a trajectory to reach $136.8 billion by 2021.[90] The IoT is 
the name given to the network of devices or “things” that have 
the ability to communicate with one and other over wireless 
networks and then report data to a cloud-based server. This 
allows the user access to these “things” wherever and whenever 
they require it, in the case of medical IoT, for example, this 
could be IMDs or ward-based monitoring systems. On top 
of this the cloud-based storage and communication of these 
“things” allows for “big data,” large volumes of specific and 
unspecific personal data, acquisition to establish trends and 
predictions, for example, within the hospital and commu-
nity care.[91,92] The impact of these devices on health care is 
becoming and will furthermore become the standardized norm 
adding to the decentralized health-care model that the smart city 
will enable and drive forward.
Modern connected medical devices allow physicians 24 h 
access to a vast array of monitoring options within a hospital 
and with enabled IMDs allowing remote monitoring of the 
patient through the IoT. With the IoT driving the future of 
IMDs the accessibility of wireless devices has become a major 
security concern.[93] Several methods have been described 
detailing the architectures of how this can be achieved. Limiting 
the access to approved individuals within health-care system is 
one option while using dual authentication through a patients 
internal electrocardiogram and their finger print to authenticate 
access to patients data has also been put forward.[94,95] Constant 
wireless communication carries the risk of malicious attack, 
interference with other wireless devices, and an increased 
battery drain.[96,97] With the privacy of personal data a hot topic 
securing the device data and network needs is an important 
consideration that should not be underestimated from the first 
prototype all the way through to the finished commercial entity 
in order to reach regulatory approval.
The average time for devices to reach regulatory approval 
is shorter than medicines but on average it still takes 3 to 
7 years and with cost for drugs spiraling to over $1 billion it 
is also expensive.[98] Devices are classified as under the United 
States Food and Drug Administration (FDA) system have three 
classes. A class I device has low risk of illness or injury class II 
moderate risk and Class III a device that sustains the life or 
could impose high risk.[99] The FDA automatically classes any 
device as class III unless an exemption is granted for approval 
to enter at a lower grade which can be achieved through 
showing its equivalency to existing devices.[100] As such modi-
fying an existing approved IMD may facilitate approval, than 
for an entirely novel device. A number of devices that enter 
health care use this equivalency to get to market.[101] In addition 
to the FDA approval quality assurance in the form of ISO13485 
will need to be achieved prior to application of the standard-
izing agency, this is normal 9–12 months before market release 
but should be considered from the prototyping stage.[102]
The full integration of the stentenna is an example of 
adapting current working designs for treatment and increasing 
their functionality to prepare them for future uses. The use of 
the stent as an antenna for wireless power transfer has also 
been investigated mathematically and in vitro.[103] The impor-
tance of powering IMDs wirelessly revolves around the hazards 
associated with implanting chemical batteries within the body 
with size upon a stent also a limitation. Active devices, those 
powered by a battery, are at risk of leakage, corrosion, and pro-
duction of excess heat.[104] Transferring the power wirelessly 
to a stent or other IMD would therefore eliminate the battery 
and reduce these risks. STENTag uses radio frequency identi-
fication (RFID) to interrogate a passive sensing device, without 
an implantable battery, for proposed carotid artery stents.[105] 
In vitro testing within a submerged phantom vessel allowed 
detection of varying stenosis using this passive technology which 
compared to predetermined computational modeling. The use 
of RFID integration into a safe and potentially effective pow-
ering option however the superficial implantation in the carotid 
artery may not be as successful in arteries with thicker tissue 
layers and bone obstruction. Wireless power transfer to an 
active device offers another solution for powering IMDs.[106] 
Several other investigations into powering IMDs are suggested 
including biofuel cells and piezoelectric muscle contraction uti-
lization.[107–111] A novel approach using in vivo work into bio-
degradable batteries has been performed and would therefore 
remove the risk of chemical leakage and lends itself to the bio-
degradable stents currently being used.[112] As such, innovative 
passive and active powering methods are set to continue to be 
developed and utilized for IMDs.
The BRS is set to continue to be researched and as 
the IoT of things is set to grow the importance of biodegrad-
able sensors is noted by many. Investigations into implant-
able biodegradable sensors for IMDs are unsurprisingly 
similar to the materials used in BRS. Hwang produced 
sensors based on poly lactic acid (PLA),[113] which produces 
the co polymers of PLLA and PDLLA. The series of experi-
ments showed that PLA derivatives with the use of various 
construction steps using of silicon electrodes and magne-
sium interconnects could produce a biodegradable CMOS.[113] 
Alternatively molybdenum disulfide can be used due to its 
biocompatibility and the ease at which established manufac-
turing techniques can be used to create the components.[114] 
Pressure, strain, and temperature were all able to be detected 
in vivo via the sensor. Previous to this a biodegradable radiof-
requency antenna made from magnesium had been produced 
and successfully powered a light emitting diode.[115] Within 
the review pressure sensors were reviewed with biodegrad-
able sensors being studied,[78] furthering this a biodegradable 
pressure and strain gauge has been devolved for orthopedic 
use; however, the use of a strain gauge within a graft is a 
possible advantage in aiding PWV.[116]
6. Conclusion
The use of sensors for monitoring internal conditions within 
a vessel is now feasible. As a direct measurement of in stent 
restenosis the area is focused on pressure due to the changes 
that can occur with plaque formation, which is similar to 
pressure studies interventionist cardiologist would employ 
currently. The use of these sensors peripherally has also been 
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addressed, again with a pressure orientation, which would 
fall in line with current measurement methods but also allow 
for chronic measurement of a patient’s blood pressure. This 
aligns neatly with the Internet of Things in allowing constant 
patient monitoring and therefore enabling big data techniques 
to improve the patients future health predictions based on their 
current status. The integration of all necessary components for 
a sensor, stent, and wireless communication system remains a 
major limiting factor. With CVD a major threat and more pro-
cedures of PCI with a stent deployment being carried out yearly 
the use of sensors to monitor the vessel post procedure is likely 
to be the next evolution of the stent.
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